4D Molecular Therapeutics Appoints Kristian Humer as CFO as Company Advances Phase III Retinal Disease Programs
核心洞察
4D Molecular Therapeutics has appointed Kristian Humer (搜索) as Chief Financial Officer to lead financial strategy as the company advances multiple Phase III programs and prepares for commercial readiness.
Humer brings over two decades of experience in corporate finance and healthcare investment banking, having previously served as Managing Director at Citi (搜索)'s Healthcare Investment Banking Group and CFO at publicly traded companies Foghorn Therapeutics and Viridian Therapeutics.
The appointment comes as 4DMT's lead product candidate 4D-150 progresses through Phase III development for wet age-related macular degeneration (搜索), with a second indication in diabetic macular edema (搜索).
4D Molecular Therapeutics (Nasdaq: FDMT), a late-stage biotechnology company developing gene therapies for retinal diseases, has appointed Kristian Humer (搜索) as Chief Financial Officer as the company advances multiple Phase III programs and prepares for commercial readiness. The appointment positions the company to navigate critical late-stage development milestones and commercial planning for its lead retinal disease programs.
Executive Leadership Addition
Humer brings more than two decades of experience spanning corporate finance, strategic operations, and healthcare investment banking to 4DMT. He will lead the company's financial strategy and operations, including responsibility for financial planning, capital allocation, corporate development, and supporting strategic initiatives.
"Kristian's appointment comes at a pivotal time as we advance multiple Phase 3 programs and prepare for commercial readiness," said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. "His deep expertise in corporate finance, corporate development and strategy will help position 4DMT for long-term growth and create opportunities to maximize value for patients and shareholders."
Financial Leadership Experience
Humer's background includes serving as Managing Director in Citi (搜索)'s Healthcare Investment Banking Group from 2010 to 2021, where he advised global biopharma clients on strategic initiatives including equity financing, mergers and acquisitions, and corporate transactions. Most recently, he served as CFO of publicly traded companies Foghorn Therapeutics and Viridian Therapeutics.
"I'm excited to join 4DMT during this critical stage of development," said Humer. "As the company progresses toward late-stage clinical milestones and commercial planning, I look forward to partnering across the organization to drive financial discipline and strategic initiatives that support sustainable growth and long-term success."
Lead Program Development
4DMT's lead product candidate 4D-150 is designed as a backbone therapy for blinding retinal vascular diseases, providing multi-year sustained delivery of anti-VEGF (搜索) agents (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection. This approach aims to substantially reduce the treatment burden associated with current bolus injections.
The company's lead indication for 4D-150 is wet age-related macular degeneration (搜索), currently in Phase III development, with a second indication in diabetic macular edema (搜索). The company is also developing 4D-710, the first known genetic medicine to demonstrate successful delivery and expression of the CFTR (搜索) transgene in the lungs of people with cystic fibrosis (搜索) after aerosol delivery.
Commercial Readiness Strategy
The CFO appointment reflects 4DMT's transition toward commercial readiness as its lead programs advance through late-stage clinical development. Humer's experience with public company operations and capital markets positions the company to execute on strategic initiatives supporting sustainable growth and long-term success in the competitive retinal disease treatment landscape.